Clinical and Biological Data of the 10 Newborns Displaying an Immune Neonatal Thrombocytopenia
| Case . | Parental Mismatch . | Maternal Status . | Neonatal Platelet Count . | RD . | Treatment . | Neonatal Clinical Status . | |||
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | × 109/L . | . | . | Bleeding . | Associated Illness . | ||
| . | . | . | UC . | Nadir . | (day) . | . | . | . | . |
| 1 | HPA-1 | Anti–HPA-1a | 46 | 28 | (0) | 3 | IVIgG (day 1) | Absence | IUGR |
| 2 | HPA-1 | Anti–HPA-1a | 50 | 38 | (1) | 5 | None | Absence | Absence |
| 3 | HPA-1 | Anti–HPA-1a | 2 | 2 | (0) | 6 | IVIgG (day 0) | Extensive purpura | Absence |
| 4 | HPA-1 | Anti–HPA-1a | 20 | 20 | (0) | 0 | IVIgG, platelets (day 0) | Hemorrhage after PUBS | Porencephaly |
| 5 | HPA-1 | No anti–HPA-1a | 135 | 17 | (5) | 7 | IVIgG (day 5) | Absence | Acute fetal distress |
| 6 | None | Thrombocytopenia, HIV infection | 74 | 66 | (1) | ? | None | Absence | Absence |
| 7 | None | AITP, anti-GPIbIX | 143 | 106 | (5) | 8 | None | Absence | Absence |
| 8 | HPA-5 | AITP, anti–HPA-5a | 49 | 30 | (9) | 15 | IVIgG, (days 1, 3, 4) | Absence | Absence |
| 9 | HPA-5 | AITP, anti-GPIbIX, anti–HPA-5b | 113 | 55 | (2) | 5 | None | Meningeal hemorrhage | Transient respiratory distress |
| 10 | HPA-5 | Compensated thrombocytolysis, anti-GPIbIX | 8 | 2 | (0) | 60 | Corticosteroids (1 mg/d) | Purpura | Absence |
| Case . | Parental Mismatch . | Maternal Status . | Neonatal Platelet Count . | RD . | Treatment . | Neonatal Clinical Status . | |||
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | × 109/L . | . | . | Bleeding . | Associated Illness . | ||
| . | . | . | UC . | Nadir . | (day) . | . | . | . | . |
| 1 | HPA-1 | Anti–HPA-1a | 46 | 28 | (0) | 3 | IVIgG (day 1) | Absence | IUGR |
| 2 | HPA-1 | Anti–HPA-1a | 50 | 38 | (1) | 5 | None | Absence | Absence |
| 3 | HPA-1 | Anti–HPA-1a | 2 | 2 | (0) | 6 | IVIgG (day 0) | Extensive purpura | Absence |
| 4 | HPA-1 | Anti–HPA-1a | 20 | 20 | (0) | 0 | IVIgG, platelets (day 0) | Hemorrhage after PUBS | Porencephaly |
| 5 | HPA-1 | No anti–HPA-1a | 135 | 17 | (5) | 7 | IVIgG (day 5) | Absence | Acute fetal distress |
| 6 | None | Thrombocytopenia, HIV infection | 74 | 66 | (1) | ? | None | Absence | Absence |
| 7 | None | AITP, anti-GPIbIX | 143 | 106 | (5) | 8 | None | Absence | Absence |
| 8 | HPA-5 | AITP, anti–HPA-5a | 49 | 30 | (9) | 15 | IVIgG, (days 1, 3, 4) | Absence | Absence |
| 9 | HPA-5 | AITP, anti-GPIbIX, anti–HPA-5b | 113 | 55 | (2) | 5 | None | Meningeal hemorrhage | Transient respiratory distress |
| 10 | HPA-5 | Compensated thrombocytolysis, anti-GPIbIX | 8 | 2 | (0) | 60 | Corticosteroids (1 mg/d) | Purpura | Absence |
Abbreviations: UC, umbilical cord sampling; IUGR, intrauterine growth retardation; (day), day when the nadir of platelet count was reached; IVIgG, intravenous immunoglobulins; RD, recovery day; PUBS, percutaneous umbilical blood sampling.